Postmenopausal osteoporosis: standard diagnostic and therapeutic practice

Bilezikian JP, Khan AA, Potts JT jr. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. J Clin Endocrinol Metab 2009; 94(2): 335–339.

Genant HK, Wu CY, van Kuijk C et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8(9): 1137–1148.

Hans DB, Shepherd JA, Schwartz EN et al. Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 2008; 11(1): 188–206.

Hernlund E, Svedbom A, Ivergard M et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013; 8:136. Dostupné z DOI: <http://doi: 10.1007/s11657–013–0136–1>.

Kanis JA, Borgstrom F, Compston J et al. SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 2013; 8: 144. Dostupné z DOI: <http://doi: 10.1007/s11657–013–0144–1>.

Kanis JA, Johnell O, Oden A et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19(4): 385–397.

Kanis JA, McCloskey EV, Johansson Het al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013; 24(1): 23–57.

Cosman F, de Beur SJ, LeBoff MS et al. National Osteoporosis Foundation: Clinician´s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010. Osteoporos Int 2014; 25(10): 2359–2381.

Odborné usmernenie MZ SR pre diagnostiku a liečbu osteoporózy. Vestník MZ SR, čiastka 9–16, ročník 54, zo dňa 1. marca 2006.

Odborné usmernenie MZ SR pre diagnostiku a liečbu glukokortikoidmi indukovanej osteoporózy (GIOP). Vestník MZ SR, čiastka 51–53, ročník 57, zo dňa 13. novembra 2009.

Odborné usmernenie MZ SR o diagnostike a liečbe pacienta po osteoporotických zlomeninách. Vestník MZ SR, čiastka 1–3, ročník 59, zo dňa 4. februára 2011.

Official Positions of the International Society for Clinical Densitometry 2015. Dostupné z WWW: <http://www.iscd.org/official-positions/2015-iscd-official-positions-adult>.

Payer J, Killinger Z et al. Osteoporóza. Herba: Bratislava 2012. ISBN 978–80–8971–94–1.

Payer J, Borovský M (eds). Osteoporóza u vybranných ochorení. Herba: Bratislava 2014. ISBN 978–80–8963–11–93.

Payer J, Brazdilova K, Jackuliak P. Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options. Drug Healthc Patient Saf 2010; 2: 49–59.

Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357(20): 2028–2039.

Svedbom A, Hernlund E, Ivergard M et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013; 8:137. Dostupné z DOI: http://doi: 10.1007/s11657–013–0137–0>.

Watts NB, Adler RA, Bilezikian JP et al. Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2012; 97(6): 1802–1822.